Get the Stockscreener App
2.20
1.85%
0.04
Generation Bio Co stock is traded at $2.20, with a volume of 109.96K.
It is up +1.85% in the last 24 hours and down -11.29% over the past month.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$2.16
Open:
$2.14
24h Volume:
109.96K
Relative Volume:
1.13
Market Cap:
$144.16M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-1.0577
EPS:
-2.08
Net Cash Flow:
$-60.14M
1W Performance:
-7.95%
1M Performance:
-11.29%
6M Performance:
-30.60%
1Y Performance:
+66.67%
1-Day Range:
$2.14
$2.31
1-Week Range:
$2.14
$2.45
52-Week Range:
$1.02
$4.65
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Promising Penny Stocks On US Exchanges In November 2024 - Simply Wall St
Researchers Seek to Unlock the Secrets to Human Longevity - Securities.io
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Bullish Generation Bio Insiders Loaded Up On US$778.9k Of Stock - Yahoo Finance
ST Launches AI-enhanced Bio-Sensing Chip for Next-gen Wearables - EE Times India
Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 13.4% in October - MarketBeat
Generation Bio's SWOT analysis: innovative gene therapy stock faces timeline hurdles - Investing.com
Generation Bio (NASDAQ:GBIO) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT - The Bakersfield Californian
Generation Bio Announces the Presentation of Preclinical - GlobeNewswire
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress - StockTitan
Cubist Systematic Strategies LLC Has $54,000 Stake in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 6.1% in September - MarketBeat
Viral And Non-Viral Vector Manufacturing Market Report 2024-2033 | Size, Trends, Outlook - WhaTech
Alnylam’s founder brings in a $135M series A for City Therapeutics - BioWorld Online
City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine - Pulse 2.0
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine - BioSpace
Renaissance Technologies LLC Sells 28,100 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio's SWOT analysis: innovative dna tech propels stock potential - Investing.com India
Generation Bio Co. (NASDAQ:GBIO) Sees Large Increase in Short Interest - MarketBeat
Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 13.8% in September - Defense World
Rhumbline Advisers Buys 5,430 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Bank of New York Mellon Corp Has $527,000 Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Comparative life cycle assessment for PBAT from fossil-derived and 2nd generation biobased feedstocks - ScienceDirect.com
GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy - BioSpace
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech
GrowGeneration Corp [GRWG] Investment Guide: What You Need to Know - Knox Daily
Gen Digital: Strong Growth, Good Fundamentals, And Decent Price Action Make A Buy - Seeking Alpha
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat
Insider Sale Alert: Gen Digital Inc [GEN] – Is it Time to sell? - Knox Daily
Cornercap Investment Counsel Inc. Sells 16,746 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio Co. (NASDAQ:GBIO) Shares Bought by Acadian Asset Management LLC - Defense World
Choreo LLC Takes $776,000 Position in Genmab A/S (NASDAQ:GMAB) - MarketBeat
Generation Bio Co. (NASDAQ:GBIO) Shares Sold by Los Angeles Capital Management LLC - Defense World
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference - ForexTV.com
Moderna falls on R&D cuts, filing delays, terminated programs - BioWorld Online
Generation Bio (NASDAQ:GBIO) Stock Price Down 0.4% - MarketBeat
Holdings of Generation Bio Co (GBIO) are aligned with the stars - SETE News
Financial Metrics Check: Generation Bio Co (GBIO)’s Ratios for Trailing Twelve Months - The Dwinnex
The Generation Bio Co (GBIO) had a good session last reading, didn’t it? - US Post News
Next Generation Bio-therapeutics Market to Exhibit - openPR
Pipeline Co-Creation - Evotec
Vanguard Group Inc. Buys 18,205 Shares of Generation Bio Co. (NASDAQ:GBIO) - Defense World
Q3 2024 Earnings Forecast for Generation Bio Co. (NASDAQ:GBIO) Issued By Wedbush - Defense World
Research Analysts Set Expectations for Generation Bio Co.'s Q3 2024 Earnings (NASDAQ:GBIO) - MarketBeat
Generation Bio Co. (NASDAQ:GBIO) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Generation Bio Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Generation Bio (NASDAQ:GBIO) Stock Rating Reaffirmed by Wedbush - MarketBeat
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates - MSN
Generation Bio Co (GBIO) Q2 2024 Earnings: Revenue Surges to $4. - GuruFocus.com
Generation Bio Reports Second Quarter 2024 Financial Results - Marketscreener.com
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Generation Bio Co Stock (GBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paone Antoinette | CHIEF OPERATING OFFICER |
Jul 01 '24 |
Sale |
2.74 |
6,719 |
18,410 |
13,807 |
| Paone Antoinette | CHIEF OPERATING OFFICER |
Jan 02 '24 |
Sale |
1.62 |
2,445 |
3,961 |
5,828 |
| Samayoa Phillip | CHIEF STRATEGY OFFICER |
Jan 02 '24 |
Sale |
1.62 |
2,445 |
3,961 |
107,256 |
| Appelhans Dannielle | Director |
Dec 08 '23 |
Buy |
1.79 |
7,363 |
13,180 |
7,363 |
| Appelhans Dannielle | Director |
Dec 08 '23 |
Buy |
1.82 |
637 |
1,159 |
12,637 |
| Appelhans Dannielle | Director |
Dec 04 '23 |
Buy |
1.50 |
12,000 |
18,000 |
12,000 |
| Quinn Anthony G. | Director |
Dec 01 '23 |
Buy |
1.41 |
88,495 |
124,778 |
88,495 |
| Rowland Charles A Jr | Director |
Dec 01 '23 |
Buy |
1.31 |
192,960 |
252,778 |
384,757 |
| Rowland Charles A Jr | Director |
Dec 04 '23 |
Buy |
1.50 |
150,000 |
225,000 |
534,757 |
| Nicholson Donald William | Director |
Dec 01 '23 |
Buy |
1.44 |
100,000 |
144,000 |
213,576 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):